Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib

Academic Radiology

Volumn 18, Issue 1, 2011, Pages 89-96

  Spira, Daniel ^a   Fenchel, Michael ^a   Lauer, Ulrich M ^a   Claussen, Claus D ^a   Gregor, Michael ^a   Bitzer, Michael ^a   Horger, Marius ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Hepatocellular carcinoma monitoring; MR imaging; Response Evaluation Criteria in Solid Tumors; Sorafenib

Indexed keywords

ALPHA FETOPROTEIN; GADOLINIUM PENTETATE; SORAFENIB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER HISTOLOGY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PRIORITY JOURNAL; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; LIVER; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NECROSIS; PYRIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 78649907746     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acra.2010.08.008     Document Type: Article

References (29)

1. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
2. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
3. Horger M., Lauer U.M., Schraml C., et al. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer 2009, 9:208.
4. Schraml C., Schwenzer N.F., Martirosian P., et al. Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol 2009, 193:W301-W307.
5. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
6. Llovet J.M., Di Bisceglie A.M., Bruix J., et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008, 100:698-711.
7. Forner A., Ayuso C., Varela M., et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?. Cancer 2009, 115:616-623.
8. Eisenhauer E.A. Response evaluation: beyond RECIST. Ann Oncol 2007, 18(suppl):ix29-ix32.
9. Michaelis L.C., Ratain M.J. Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 2006, 6:409-414.
10. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
11. Abou-Alfa G.K. Hepatocellular carcinoma: molecular biology and therapy. Semin Oncol 2006, 33(suppl):S79-S83.
12. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001, 35:421-430.
13. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434.
14. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.
15. Chan S.L., Mo F.K., Johnson P.J., et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 2009, 27:446-452.
16. Efremidis S.C., Hytiroglou P., Matsui O. Enhancement patterns and signal-intensity characteristics of small hepatocellular carcinoma in cirrhosis: pathologic basis and diagnostic challenges. Eur Radiol 2007, 17:2969-2982.
17. Stacchiotti S., Collini P., Messina A., et al. High-grade soft-tissue sarcomas: tumor response assessment-pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 2009, 251:447-456.
18. Choi H., Charnsangavej C., Faria S.C., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007, 25:1753-1759.
19. Benjamin R.S., Choi H., Macapinlac H.A., et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007, 25:1760-1764.
20. Crabb S.J., Patsios D., Sauerbrei E., et al. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol 2009, 27:404-410.
21. Liapi E., Geschwind J.F., Vossen J.A., et al. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR Am J Roentgenol 2008, 190:67-73.
22. Scher H.I., Morris M.J., Kelly W.K., et al. Prostate cancer clinical trial end points: " RECIST" ing a step backwards. Clin Cancer Res 2005, 11:5223-5232.
23. van Klaveren R.J., Aerts J.G., de Bruin H., et al. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer 2004, 43:63-69.
24. Byrne M.J., Nowak A.K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004, 15:257-260.
25. Gopinath G., Ahmed A., Buscombe J.R., et al. Prediction of clinical outcome in treated neuroendocrine tumours of carcinoid type using functional volumes on 111In-pentetreotide SPECT imaging. Nucl Med Commun 2004, 25:253-257.
26. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
27. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
28. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
29. Bruix J., Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.